Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease

2.50
Hdl Handle:
http://hdl.handle.net/10547/593442
Title:
Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease
Authors:
von Haehling, Stephan; Papassotiriou, Jana; Morgenthaler, Nils G.; Hartmann, Oliver; Doehner, Wolfram; Stellos, Konstantinos; Wurster, Thomas; Schuster, Andreas; Nagel, Eike; Gawaz, Meinrad; Bigalke, Boris
Abstract:
Background C-terminal portion of provasopressin (copeptin) has recently been discussed as a novel biomarker for the early rule-out of acute myocardial infarction (AMI). The aim is to investigate the prognostic value of copeptin with regard to mortality and morbidity in patients with symptomatic coronary artery disease (CAD). Methods We consecutively recruited a cath lab cohort of 2,700 patients (74.1% male; AMI, n = 1316; stable angina pectoris, n = 1384) presenting to the emergency department of a large primary care hospital. All patients received coronary angiography. Copeptin and other laboratory markers were sampled at the time of presentation or in the cath lab. Clinical outcomes were assessed by hospital chart analysis and telephone interviews. 2621 patients (97.1%) have been successfully followed-up at three months. The primary endpoint was a combined endpoint of rehospitalization for cardiovascular events, stroke, and all-cause death. Results Using receiver operating characteristic curves, we calculated areas under the curve of 0.703 (95%confidence interval(CI):0.681–0.725) for the composite endpoint after three months (myocardial reinfarction, stroke, all-cause death;n = 183), and 0.770 (95%CI:0.736–0.803) for all-cause death (n = 76) for copeptin. A cutoff value of 21.6 pmol/L for the composite endpoint yielded a sensitivity of 56.3% and a specificity of 78.6%. The predictive performance of copeptin was independent of other clinical variables or cardiovascular risk factors, and superior to that of troponin I or other cardiac biomarkers (all:P < 0.0001). Conclusions Copeptin may help in the prediction of major adverse cardiovascular events in patients with symptomatic CAD. Further studies should substantiate the findings and support the suggested cutoff value of the present study.
Affiliation:
Charité Medical School; Biotechnology Centre Hennigsdorf/Berlin; Johann Wolfgang Goethe University Frankfurt; Eberhard-Karls-Universität Tübingen; King's College London
Citation:
von Haehling, S. et al (2012) 'Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease' International Journal of Cardiology 162 (1):27
Publisher:
Elsevier
Journal:
International Journal of Cardiology
Issue Date:
Dec-2012
URI:
http://hdl.handle.net/10547/593442
DOI:
10.1016/j.ijcard.2011.12.105
Additional Links:
http://linkinghub.elsevier.com/retrieve/pii/S0167527311023011
Type:
Article
Language:
en
ISSN:
0167-5273
Appears in Collections:
IHR Institute for Health Research

Full metadata record

DC FieldValue Language
dc.contributor.authorvon Haehling, Stephanen
dc.contributor.authorPapassotiriou, Janaen
dc.contributor.authorMorgenthaler, Nils G.en
dc.contributor.authorHartmann, Oliveren
dc.contributor.authorDoehner, Wolframen
dc.contributor.authorStellos, Konstantinosen
dc.contributor.authorWurster, Thomasen
dc.contributor.authorSchuster, Andreasen
dc.contributor.authorNagel, Eikeen
dc.contributor.authorGawaz, Meinraden
dc.contributor.authorBigalke, Borisen
dc.date.accessioned2016-01-14T11:32:07Zen
dc.date.available2016-01-14T11:32:07Zen
dc.date.issued2012-12en
dc.identifier.citationvon Haehling, S. et al (2012) 'Copeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery disease' International Journal of Cardiology 162 (1):27en
dc.identifier.issn0167-5273en
dc.identifier.doi10.1016/j.ijcard.2011.12.105en
dc.identifier.urihttp://hdl.handle.net/10547/593442en
dc.description.abstractBackground C-terminal portion of provasopressin (copeptin) has recently been discussed as a novel biomarker for the early rule-out of acute myocardial infarction (AMI). The aim is to investigate the prognostic value of copeptin with regard to mortality and morbidity in patients with symptomatic coronary artery disease (CAD). Methods We consecutively recruited a cath lab cohort of 2,700 patients (74.1% male; AMI, n = 1316; stable angina pectoris, n = 1384) presenting to the emergency department of a large primary care hospital. All patients received coronary angiography. Copeptin and other laboratory markers were sampled at the time of presentation or in the cath lab. Clinical outcomes were assessed by hospital chart analysis and telephone interviews. 2621 patients (97.1%) have been successfully followed-up at three months. The primary endpoint was a combined endpoint of rehospitalization for cardiovascular events, stroke, and all-cause death. Results Using receiver operating characteristic curves, we calculated areas under the curve of 0.703 (95%confidence interval(CI):0.681–0.725) for the composite endpoint after three months (myocardial reinfarction, stroke, all-cause death;n = 183), and 0.770 (95%CI:0.736–0.803) for all-cause death (n = 76) for copeptin. A cutoff value of 21.6 pmol/L for the composite endpoint yielded a sensitivity of 56.3% and a specificity of 78.6%. The predictive performance of copeptin was independent of other clinical variables or cardiovascular risk factors, and superior to that of troponin I or other cardiac biomarkers (all:P < 0.0001). Conclusions Copeptin may help in the prediction of major adverse cardiovascular events in patients with symptomatic CAD. Further studies should substantiate the findings and support the suggested cutoff value of the present study.en
dc.language.isoenen
dc.publisherElsevieren
dc.relation.urlhttp://linkinghub.elsevier.com/retrieve/pii/S0167527311023011en
dc.rightsArchived with thanks to International Journal of Cardiologyen
dc.subjectcopeptinen
dc.subjectprognostic factoren
dc.subjectcoronary artery diseaseen
dc.titleCopeptin as a prognostic factor for major adverse cardiovascular events in patients with coronary artery diseaseen
dc.typeArticleen
dc.contributor.departmentCharité Medical Schoolen
dc.contributor.departmentBiotechnology Centre Hennigsdorf/Berlinen
dc.contributor.departmentJohann Wolfgang Goethe University Frankfurten
dc.contributor.departmentEberhard-Karls-Universität Tübingenen
dc.contributor.departmentKing's College Londonen
dc.identifier.journalInternational Journal of Cardiologyen
All Items in UOBREP are protected by copyright, with all rights reserved, unless otherwise indicated.